Evidence map›Paper›PMID 26707323›Full record

ArticleTransplantation proceedings2015

Race, Calcineurin Inhibitor Exposure, and Renal Function After Solid Organ Transplantation.

L Yessayan, A Shafiq, E Peterson, K Wells, Y Hu, L K Williams, D Lanfear

Abstract readMulticenter Study
In one paragraph

Article in Transplantation proceedings, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

L YessayanDepartment of Internal Medicine, Henry Ford Hospital, Detroit, Michigan, United States; Division of Nephrology, Henry Ford Hospital, Detroit, Michigan, United States. Electronic address: lyessay1@hfhs.org.
A ShafiqDepartment of Internal Medicine, Henry Ford Hospital, Detroit, Michigan, United States.
E PetersonHeart and Vascular Institute, Henry Ford Hospital, Detroit, Michigan, United States.
K WellsHeart and Vascular Institute, Henry Ford Hospital, Detroit, Michigan, United States.
Y HuHeart and Vascular Institute, Henry Ford Hospital, Detroit, Michigan, United States.
L K WilliamsDepartment of Internal Medicine, Henry Ford Hospital, Detroit, Michigan, United States; Heart and Vascular Institute, Henry Ford Hospital, Detroit, Michigan, United States.
D LanfearDepartment of Internal Medicine, Henry Ford Hospital, Detroit, Michigan, United States; Heart and Vascular Institute, Henry Ford Hospital, Detroit, Michigan, United States; Center for Health Services Research, Henry Ford Hospital, Detroit, Michigan, United States.

Funding

PHARMACOGENOMICS OF INHALED CORTICOSTEROID RESPONSIVENESS IN PATIENTS WITH ASTHMAR01AI079139 · NIAID · HENRY FORD HEALTH SYSTEM · PI WILLIAMS, KEOKI · 2009 to 2013
$3.9M
Impact of Race and Genetic Factors on Beta-blocker Effectiveness in Heart FailureR01HL103871 · NHLBI · HENRY FORD HEALTH SYSTEM · PI LANFEAR, DAVID E · 2011 to 2015
$3.5M
Mechanism of Endotoxin's Effect On Allergy RiskR01AI061774 · NIAID · HENRY FORD HEALTH SYSTEM · PI WILLIAMS, KEOKI · 2004 to 2008
$2.9M
VALIDATION OF ADHERENCE DATA--USE IN CLINICAL PRACTICER01DK064695 · NIDDK · HENRY FORD HEALTH SYSTEM · PI WILLIAMS, KEOKI · 2003 to 2010
$2.7M
USING INFORMATION TECHNOLOGY TO IMPROVE ASTHMA ADHERENCER01HL079055 · NHLBI · HENRY FORD HEALTH SYSTEM · PI WILLIAMS, KEOKI · 2005 to 2008
$1.4M
Pharmacogenetics of the B-type Natriuretic Peptide PathwayK23HL085124 · NHLBI · HENRY FORD HEALTH SYSTEM · PI LANFEAR, DAVID E · 2008 to 2012
$632k
NHLBI NIH HHS K23 HL085124NHLBI NIH HHS R01 HL079055NHLBI NIH HHS R01 HL103871NIAID NIH HHS R01 AI061774NIAID NIH HHS R01 AI079139NIDDK NIH HHS R01 DK064695
6 · The paper itself

Abstract

backgroundCalcineurin-inhibitor (CNI)-induced nephrotoxicity frequently complicates transplantation. African-Americans are at a greater risk of renal failure than the general population. We investigated whether race was an effect modifier of the relationship between CNI exposure and kidney function after nonrenal solid organ transplantation.

methodsThis is a retrospective cohort study of 1609 patients who underwent initial nonrenal solid organ transplantation between January 2000 and June 2012. A central repository administrative database was queried electronically for demographics, comorbidities, and serial levels of tacrolimus, cyclosporine, and serum creatinine. Predictors of interest were total drug exposure of tacrolimus and cyclosporine (area under the concentration-time curve) and self-reported race. The outcome of interest was cumulative change in estimated glomerular filtration rate (GFR).

resultsThere were 1109 patients treated with tacrolimus (271 African-Americans) and 500 patients treated with cyclosporine (113 African Americans). A decline in GFR over time was seen with total tacrolimus exposure (-1.3 mL/min/1.73 m(2) for every 5 ng/mL·year increase in tacrolimus) and total cyclosporine exposure (-1.1 mL/min/1.73 m(2) for every 50 ng/mL·year increase in cyclosporine). However, total CNI exposure effect on estimated GFR changes did not vary by race (P interaction was 0.9 for tacrolimus and 0.6 for cyclosporine).

conclusionsTotal CNI exposure is associated with worsening kidney function among patients with nonrenal solid organ transplantation. However, African-American patients are not more vulnerable to chronic CNI-induced nephrotoxicity when compared to white patients.

Indexed as

Organ TransplantationRacial GroupsCalcineurin InhibitorsCyclosporineFemaleFollow-Up StudiesGlomerular Filtration RateGraft RejectionHumansIncidenceKidney Function TestsMaleMiddle AgedRenal InsufficiencyRetrospective StudiesSurvival RateCalcineurin InhibitorsCyclosporineTacrolimus

Identifiers

PMID26707323
PMCPMC4819428

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.